1-2 of 2
Dorota Kruk-Kwapisz
Close
Sort by
Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Dorota Kruk-Kwapisz, Oscar Boutros Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew T Stefka, Ken Jiang, Jennifer H Cooperrider, Ben A Derman, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4715.
https://doi.org/10.1182/blood-2023-189850
Published: 2023
Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Tadeusz Kubicki, Ben A Derman, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wrobel, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Dorota Kruk-Kwapisz, Andrzej J Jakubowiak, Dominik Dytfeld
Journal: Blood
Blood (2023) 142 (Supplement 1): 3344.
https://doi.org/10.1182/blood-2023-189537
Published: 2023